Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/236424
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia |
Autor: | Bayón-Calderón, Fátima; Toribio, María Luisa CSIC ORCID; González-García, Sara CSIC ORCID | Palabras clave: | T-cell acute lymphoblastic leukemia Immunotherapy Monoclonal antibodies Chimeric antigen receptor Relapse Leukemia-initiating cells |
Fecha de publicación: | 16-oct-2020 | Editor: | Molecular Diversity Preservation International | Citación: | International Journal of Molecular Sciences 21 (2020) | Resumen: | T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disorder that results from the progressive accumulation of genomic alterations in T-cell precursors developing in the thymus. T-ALL is characterized by the infiltration of bone marrow by immature T-cell lymphoblasts, while immature T-cell tumors characterized by a thymic mass and limited bone marrow infiltration are instead diagnosed as T-cell lymphoblastic lymphoma (T-LBL). T-ALL was described as an independent disease in the 1970s, after finding thymus-associated markers expressed on the surface of leukemic cells from pediatric patients [1]. Its incidence is higher in children than in adults (up to 25% and 15% of newly diagnosed ALL cases, respectively) [2], and it is twice as prevalent in males as in females [3]. Patients with T-ALL are frequently classified as high-risk due to the unfavorable features of the disease that include high leukocyte count, hematopoietic failure, and medullar and extramedullar infiltration with high probability of a ectation of the central nervous system (CNS), which represents a frequent site of relapse [4]. In 1995, the European Group for Immunological Characterization of Leukemias (EGIL) established a classification of different clinically relevant T-ALL subtypes based on the expression of cell surface markers corresponding to sequential intrathymic T-cell developmental stages [5]: pro-T, pre-T, cortical and mature T-ALL (Figure 1). However, in recent years, improved genomic and transcriptomic techniques have provided new insights into the characterization of the prevalent genetic lesions involved in T-ALL pathogenesis [6–8], which has proved more valuable for risk-stratification of patients at the time of diagnosis [9–11]. Detection of translocations of enhancers or promoters of T-cell receptor (TCR) genes to other chromosomal regions helped the identification of the first T-ALL oncogenes, | Versión del editor: | http://dx.doi.org/10.3390/ijms21207685 | URI: | http://hdl.handle.net/10261/236424 | DOI: | 10.3390/ijms21207685 | Identificadores: | doi: 10.3390/ijms21207685 issn: 1422-0067 |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ToribioML_FactsandChallenges.pdf | 1,94 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
75
checked on 24-abr-2024
Download(s)
123
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons